GCANRx Announces Uplisting to New Market Tier

Core Insights - Greater Cannabis Company, Inc. has received approval to transition to the OTCID Basic Market, effective July 1, 2025, marking a significant milestone in its capital market strategy [1][2][3] Group 1: Company Overview - Greater Cannabis Company is a clinical stage biopharmaceutical company focused on developing cannabinoid therapeutics and consumer products, particularly for neuropsychiatric disorders [5] - The company's mission is to provide innovative cannabis-based treatments to address unmet medical needs globally [5] Group 2: Market Transition - The transition to the OTCID Basic Market signifies a commitment to higher standards of transparency, compliance, and corporate governance, enhancing visibility and credibility with investors [2][3] - Companies in the OTCID Basic Market must meet stringent financial standards and comply with U.S. securities laws [2] Group 3: Management Perspective - The CEO of Greater Cannabis Company expressed excitement about the uplist to OTCID, highlighting its potential to increase shareholder base, liquidity, and transparency in trading [3]